Here's Why Arbutus (ABUS) Surged in Q3 [Yahoo! Finance]
Arbutus Biopharma Corporation (ABUS)
Last arbutus biopharma corporation earnings: 11/6 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.arbutusbio.com/node/5806
Company Research
Source: Yahoo! Finance
here . Tourlite Fund, LP Founder Class returned 4.5% for Q3 2024 and 13.8% year-t0-date while the S&P 500 Index returned 5.9% and 9.3%, respectively. In addition, please check the fund's top five holdings to know its best picks in 2024. Tourlite Capital Management highlighted stocks like Arbutus Biopharma Corporation (NASDAQ: ABUS ), in the third quarter 2024 investor letter. Arbutus Biopharma Corporation (NASDAQ:ABUS) is a biopharmaceutical company that develops novel therapeutics for HBV infection. The one-month return of Arbutus Biopharma Corporation (NASDAQ:ABUS) was -3.20%, and its shares gained 75.36% of their value over the last 52 weeks. On December 5, 2024, Arbutus Biopharma Corporation (NASDAQ:ABUS) stock closed at $3.6300 per share with a market capitalization of $687.856 million. Tourlite Capital Management stated the following regarding Arbutus Biopharma Corporation (NASDAQ:ABUS) in its Q3 2024 investor letter: "While our primary interest in Arbutus Biopharma Corpor
Show less
Read more
Impact Snapshot
Event Time:
ABUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABUS alerts
High impacting Arbutus Biopharma Corporation news events
Weekly update
A roundup of the hottest topics
ABUS
News
- Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors [Yahoo! Finance]Yahoo! Finance
- Whitefort Capital Sends Letter to Arbutus Biopharma Board of DirectorsBusiness Wire
- Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside ChatGlobeNewswire
- Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.MarketBeat
- Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
ABUS
Earnings
- 11/6/24 - Miss
ABUS
Sec Filings
- 12/6/24 - Form EFFECT
- 11/15/24 - Form 8-K
- 11/14/24 - Form SC
- ABUS's page on the SEC website